Metastatic TNBC patients treated with PBCT tended to have a higher response rate, without a significant improvement of PFS or OS, compared with other subtypes. Toxicity was acceptable. Longer observation and further analysis are warranted.

Figure 1. Evidence of rapid tumor regrowth following bevacizumab cessation, within 1 month, with accelerated kinetics in patient 2 (A) before first BV treatment, (B) during first BV treatment, before surgery, (C) 1 month after colon and liver surgery and (D) during second BV treatment, after surgery.

659MOAvelumab (A) as the basis of neoadjuvant chemotherapy (NAC) regimen in platinum eligible and ineligible patients (pts) with non-metastatic muscle invasive bladder cancer (NM-MIBC)